Characterization of B7H6, an endogenous ligand for the NK cell activating receptor NKp30, reveals the identity of two different soluble isoforms during normal human pregnancy

Immunobiology ◽  
2018 ◽  
Vol 223 (1) ◽  
pp. 57-63 ◽  
Author(s):  
Jorge Gutierrez-Franco ◽  
Rodolfo Hernandez-Gutierrez ◽  
Miriam Ruth Bueno-Topete ◽  
Jesse Haramati ◽  
Rosa Elena Navarro-Hernandez ◽  
...  
1988 ◽  
Vol 25 (3) ◽  
pp. 165-172 ◽  
Author(s):  
Jelka Gabrilovac ◽  
Josip Zadjelović ◽  
Maja Osmak ◽  
Ernest Suchanek ◽  
Željko Županović ◽  
...  

2021 ◽  
Vol 224 (2) ◽  
pp. S215-S216
Author(s):  
Jayasri Basu ◽  
Yingyi Wu ◽  
Sara Oraee ◽  
Diana Encalada ◽  
Aruna Mishra ◽  
...  

1978 ◽  
Vol 21 (1) ◽  
pp. 42-50 ◽  
Author(s):  
O. Eremin ◽  
R. R. A. Coombs ◽  
D. Plumb ◽  
J. Ashby

2007 ◽  
Vol 74 (1-2) ◽  
pp. 163-169 ◽  
Author(s):  
Attila Molvarec ◽  
János Rigó ◽  
Bálint Nagy ◽  
Szilvia Walentin ◽  
János Szalay ◽  
...  

2013 ◽  
Vol 123 (10) ◽  
pp. 4264-4272 ◽  
Author(s):  
Shiqiu Xiong ◽  
Andrew M. Sharkey ◽  
Philippa R. Kennedy ◽  
Lucy Gardner ◽  
Lydia E. Farrell ◽  
...  
Keyword(s):  
Nk Cell ◽  

Blood ◽  
2002 ◽  
Vol 99 (12) ◽  
pp. 4400-4405 ◽  
Author(s):  
Suzanne Burns ◽  
Murat O. Arcasoy ◽  
Li Li ◽  
Elizabeth Kurian ◽  
Katri Selander ◽  
...  

A drug that specifically inhibits erythropoiesis would be clinically useful. The erythropoietin (Epo) mutant Epo (R103A) could potentially be used for this purpose. Epo (R103A) has a single amino acid substitution of alanine for arginine at position 103. Because of this mutation, Epo (R103A) is only able to bind to one of the 2 subunits of the erythropoietin receptor (EpoR) homodimer and is thus a competitive inhibitor of Epo activity. To produce large quantities of Epo (R103A) to test in animal models of thalassemia and sickle cell disease, we expressed and purified recombinant Epo (R103A) from the yeast Pichia pastoris. Using this method milligram quantities of highly purified Epo (R103A) are obtained. The yeast-expressed Epo (R103A) is properly processed and glycosylated and specifically inhibits Epo-dependent cell growth and125I-Epo binding. Epo (R103A) does not, however, directly induce apoptosis in 32D cells expressing EpoR. Epo (R103A) inhibits erythropoiesis of human CD34+ hematopoietic cells and completely blocks erythroid burst-forming unit formation in normal human bone marrow colony assays. Yeast-expressed Epo (R103A) is a specific inhibitor of primary erythropoiesis suitable for testing in animal models.


2009 ◽  
Vol 18 (10) ◽  
pp. 1417-1422 ◽  
Author(s):  
Katalin Dezső ◽  
Sándor Paku ◽  
Veronika Papp ◽  
Eszter Turányi ◽  
Peter Nagy

Sign in / Sign up

Export Citation Format

Share Document